Geeta Gulati

4.6k total citations · 1 hit paper
18 papers, 879 citations indexed

About

Geeta Gulati is a scholar working on Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Geeta Gulati has authored 18 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cardiology and Cardiovascular Medicine, 9 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Geeta Gulati's work include Chemotherapy-induced cardiotoxicity and mitigation (14 papers), Cardiac Imaging and Diagnostics (8 papers) and Cancer-related cognitive impairment studies (6 papers). Geeta Gulati is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (14 papers), Cardiac Imaging and Diagnostics (8 papers) and Cancer-related cognitive impairment studies (6 papers). Geeta Gulati collaborates with scholars based in Norway, Germany and United Kingdom. Geeta Gulati's co-authors include Torbjørn Omland, Siri Lagethon Heck, Jürgen Geisler, Helge Røsjø, Kjetil Steine, Berit Gravdehaug, Anne Hansen Ree, Pavel Hoffmann, Jeanette Schulz‐Menger and Morten Wang Fagerland and has published in prestigious journals such as Circulation, Cancer Research and European Heart Journal.

In The Last Decade

Geeta Gulati

16 papers receiving 864 citations

Hit Papers

Prevention of cardiac dysfunction during adjuvant breast ... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
    2016 440 citations Geeta Gulati, Siri Lagethon Heck et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geeta Gulati Norway 12 800 398 247 221 68 18 879
Berit Gravdehaug Norway 9 642 0.8× 355 0.9× 218 0.9× 173 0.8× 43 0.6× 15 729
Hari K. Narayan United States 11 537 0.7× 189 0.5× 137 0.6× 218 1.0× 70 1.0× 35 650
Emrullah Başar Türkiye 9 636 0.8× 297 0.7× 145 0.6× 153 0.7× 29 0.4× 21 702
Mary T. Vooletich United States 6 522 0.7× 421 1.1× 103 0.4× 119 0.5× 55 0.8× 12 689
G. Plataniotis Greece 5 497 0.6× 317 0.8× 137 0.6× 177 0.8× 37 0.5× 9 640
Renske Altena Sweden 11 279 0.3× 225 0.6× 103 0.4× 111 0.5× 85 1.3× 31 603
Daniela Di Lisi Italy 15 436 0.5× 178 0.4× 114 0.5× 120 0.5× 121 1.8× 59 607
Raluca Mincu Germany 13 471 0.6× 220 0.6× 115 0.5× 125 0.6× 89 1.3× 31 671
Christoph Schukro Austria 12 530 0.7× 225 0.6× 205 0.8× 98 0.4× 208 3.1× 42 831
Myrshia Woods United States 3 421 0.5× 442 1.1× 69 0.3× 117 0.5× 39 0.6× 7 570

Countries citing papers authored by Geeta Gulati

Since Specialization
Citations

This map shows the geographic impact of Geeta Gulati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geeta Gulati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geeta Gulati more than expected).

Fields of papers citing papers by Geeta Gulati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geeta Gulati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geeta Gulati. The network helps show where Geeta Gulati may publish in the future.

Co-authorship network of co-authors of Geeta Gulati

This figure shows the co-authorship network connecting the top 25 collaborators of Geeta Gulati. A scholar is included among the top collaborators of Geeta Gulati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geeta Gulati. Geeta Gulati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Omland, Torbjørn, Siri Lagethon Heck, Espen Holte, et al.. (2025). Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation. 152(16). 1136–1145. 2 indexed citations
3.
Gulati, Geeta, Agneta Månsson‐Broberg, & Birgitte Vrou Offersen. (2024). The Nordic Cardio-Oncology Society: mission and future goals. European Heart Journal. 45(21). 1869–1871.
4.
Gulati, Geeta, Anne Hansen Ree, Berit Gravdehaug, et al.. (2024). Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction. JACC CardioOncology. 6(1). 83–95. 16 indexed citations
5.
Gulati, Geeta, et al.. (2022). Sjekkpunkthemmerindusert myokarditt. Tidsskrift for Den norske legeforening. 142(18).
6.
Omland, Torbjørn, Siri Lagethon Heck, & Geeta Gulati. (2022). The Role of Cardioprotection in Cancer Therapy Cardiotoxicity. JACC CardioOncology. 4(1). 19–37. 80 indexed citations
7.
8.
9.
10.
Gulati, Geeta, Siri Lagethon Heck, Espen Holte, et al.. (2021). Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardio-Oncology. 7(1). 33–33. 26 indexed citations
11.
Månsson‐Broberg, Agneta, Jürgen Geisler, Suvi Tuohinen, et al.. (2020). Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. Current Heart Failure Reports. 17(6). 397–408. 13 indexed citations
12.
Heck, Siri Lagethon, Geeta Gulati, Pavel Hoffmann, et al.. (2017). Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. European Heart Journal - Cardiovascular Imaging. 19(5). 544–552. 29 indexed citations
13.
14.
Gulati, Geeta, Siri Lagethon Heck, Anne Hansen Ree, et al.. (2016). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. European Heart Journal. 37(21). 1671–1680. 440 indexed citations breakdown →
15.
Gulati, Geeta, Siri Lagethon Heck, Anne Hansen Ree, et al.. (2014). Abstract CT321: Prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA study. Cancer Research. 74(19_Supplement). CT321–CT321. 1 indexed citations
16.
Heck, Siri Lagethon, Geeta Gulati, Anne Hansen Ree, et al.. (2012). Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial. Cardiology. 123(4). 240–247. 38 indexed citations
17.
Gulati, Geeta, et al.. (2011). Infeksiøs endokarditt ved Ålesund sjukehus 1997-2006. Tidsskrift for Den norske legeforening. 131(2). 115–117. 1 indexed citations
18.
Gulati, Geeta, et al.. (2007). A novel method for mapping the heterogeneity in blood supply to normal and malignant tissues in the mouse dorsal window chamber. Microvascular Research. 75(2). 179–187. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Berit Gravdehaug Breakdown of academic impact, for papers by Hari K. Narayan Breakdown of academic impact, for papers by Emrullah Başar Breakdown of academic impact, for papers by Mary T. Vooletich Breakdown of academic impact, for papers by G. Plataniotis Breakdown of academic impact, for papers by Renske Altena Breakdown of academic impact, for papers by Daniela Di Lisi Breakdown of academic impact, for papers by Raluca Mincu Breakdown of academic impact, for papers by Christoph Schukro Breakdown of academic impact, for papers by Myrshia Woods
Rankless by CCL
2026